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Abstract: Coronary stents have improved very significantly the immediate and long-term results 
of percutaneous coronary interventions. However, once the vessel has healed, the scaffolding 
function of the stent is no longer needed, and the presence of a permanent metallic prosthesis 
poses important disadvantages. This has led to the idea of creating new devices that are able 
to provide mechanical support for a determined period and then disappear from the vessel, 
allowing its natural healing and avoiding the risks associated with having a permanent metallic 
cage, such as stent thrombosis. Absorbable stents currently appear as one of the most promising 
fields in interventional cardiology. The present article will review the available clinical evidence 
regarding these devices at present and their future perspectives.
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Introduction
The interventional treatment of coronary atherosclerosis has changed and improved 
significantly in the last years. The initial technique, balloon angioplasty, faced the 
important problems of acute recoil and acute vessel occlusion due to the dissection 
flaps created by the balloon.1–3 Coronary stents were created to overcome these issues. 
The initial design, bare-metal stents, were able to almost eliminate acute recoil and ves-
sel occlusion and decreased restenosis by preventing negative remodeling.4,5 However, 
their efficacy was reduced by the induction of an intense neoproliferative response 
in the vessel, which was another cause of restenosis in these devices.6   Dr  ug-eluting 
stents, incorporating an antiproliferative drug, reduced the rates of restenosis, but they 
can be associated with an irregular endothelialization, requiring prolonged double 
antiplatelet therapy to reduce the risk of late and very late stent thrombosis.7–10 All the 
aforementioned limitations led to the idea of creating new devices that are able to 
provide mechanical support while it is needed and then disappear from the vessel, 
allowing its natural healing and avoiding the risks associated with having a permanent 
metallic cage.11,12 Absorbable stents currently appear as one of the most promising 
fields in interventional cardiology. The present article will review the available clinical 
evidence regarding these devices at present and their future perspectives.
Rationale for absorbable stents in treating coronary 
artery disease
Coronary stents have improved very significantly the immediate and long-term results 
of percutaneous coronary interventions (PCIs). However, once the vessel has healed, 
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the scaffolding function of the stent is no longer needed, 
and the presence of a permanent metallic prosthesis poses 
important disadvantages. Bioresorbable stents are a field 
of growing interest in interventional cardiology because 
of their potential benefits, including the decreased risk of 
stent thrombosis at long-term follow-up, one of the most 
feared complications of metallic stents.13 The sustained 
inflammation attributed to the presence of a permanent 
foreign body in the vessel wall involved in the pathogenesis 
of stent thrombosis and recently also in the generation of 
new at  herosclerosis might be avoided by using a resorbable 
scaffold.14–16 If the stent disappears, there would not be the 
possibility of late   malapposition, another of the features 
involved in stent thrombosis.17 Once the device disappears, 
the patient would not need prolonged double antiplatelet 
therapy, thereby decreasing the risk of bleeding, especially 
in older patients. The absorption of the stent could poten-
tially lead to a recovery of the endothelial function of the 
vessel, making it responsive again to vasoactive agents. 
Further, the artery would not be permanently caged, and late 
positive remodeling in response to a physiological stimulus 
would be possible. Theoretically, an absorbable stent made 
of a polymer could be more flexible and conformable and 
would influence the shear stress pattern less than a permanent 
metallic prosthesis. It has been demonstrated that the shear 
stress pattern influences the neointima distribution after 
stent implantation.18,19 The   disappearance of the prosthesis 
would allow future treatments in the vessel if needed (either 
percutaneous or surgical) and would facilitate the access to 
side branches initially jailed by the stent. These aspects are 
of special interest in children, in whom the vessel growth 
can create a mismatch between the originally implanted 
prosthesis and the vessel size. Further, depending on their 
composition, some of these devices could be followed 
with noninvasive techniques such as multislice computed 
  tomography (MSCT) scan because they do not   create the 
artifacts originated by metallic stents. Finally, many patients 
are concerned about having a permanent implant in their 
coronary arteries and would prefer a device that is able to 
disappear after a determined period (Table 1).
Bioabsorbable stent design
With all the aforementioned potential advantages, the c  oncept 
of bioresorbable stents has created interest for a long time, 
but technical challenges have made the development of these 
devices slow. The ideal design should have   mech  anical prop-
erties that are able to provide the necessary vessel s  upport 
during the required period, must be   biocompatible, and should 
have an adequate degradation time,   disap  pearing   without 
  creating an intense inflammatory response. Apart from that, 
the device has to have good deliverability, and, ideally, it 
should be able to carry an antiproliferative drug in order to 
reduce restenosis.20 Both the selection of the material and 
the design are going to influence the success of the device. 
Regarding the material, there are two possibilities that are 
being tested: polymer-based materials that are degraded by 
hydrolysis, and absorbable metals such as magnesium-based 
alloys. Among the polymers, the one that has been used more 
frequently is polylactide (PLLA), which degrades via the 
Krebs cycle to water and carbon dioxide. Both polymers and 
magnesium alloys are less stiff than conventional metallic 
stents, and several modifications in the material processing 
(such as polymer chain orientation, increases in the molecular 
weight, or length of the polymer chain) and strut design (thick-
ness) are required to obtain an adequate radial support. The 
biocompatibility before, during, and following degradation 
is another important issue. In order to avoid inflammation or 
a toxic response in the vessel wall during degradation, the 
device should have as little material as possible, and the pro-
cess should not occur too fast to allow an adequate response 
of the tissue to the products of degradation. The vessel 
response to degradation can also be different, depending on 
the underlying plaque and on the presence of antiproliferative 
drug. Finally, in order to be introduced in the catheterization 
laboratories,   bioabsorbable devices should be easy to store 
(avoiding, if possible, the need for refrigeration), should 
Table 1 Potential advantages of bioresorbable scaffolds (BRS) 
over bare-metal stents (BMS) and drug-eluting stents (DES)
Advantage BRS BMS DES
Radial support Transient Permanent Permanent
Need for prolonged  
double antiplatelet therapy
No No Yes
Late stent thrombosis No Yes Yes
Expansive remodeling 
possible
Yes No No
Follow-up with  
noninvasive techniques
Yes No No
Permanent jailing of side 
branches
No Yes Yes
Facilitate reintervention  
in the treated segment  
(CABG or PCI)
Yes No No
Potential recovery of  
the endothelial function
Yes No No
Abbreviations: CABG, coronary artery bypass surgery; PCI, percutaneous coronary 
intervention.
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have good deliverability, and should be easy to position in 
the coronary artery. The majority of bioabsorbable materials 
have low radio-opacity, but the visualization of the device 
under fluoroscopy can be increased by the use of radio-opaque 
markers in the balloon or in the device itself.12,21
Everolimus-eluting PLLA scaffold
Different bioabsorbable coronary stents have been tested 
in clinical trials. In this paper, we will focus on the 
  everolimus-eluting PLLA scaffold (BVS) (Abbot Vascular, 
Santa Clara, CA), which has the most advanced clinical 
program, and will review briefly the clinical evidence for 
the other bioabsorbable coronary stents.
BVS design
The BVS has a bioabsorbable polymer backbone of PLLA 
with a polymer coating of poly-D,L-lactide, which con-
tains and controls the release of the antiproliferative drug 
  (everolimus). PLLA is a biocompatible material used widely 
in medicine. The polymer is degraded by hydrolysis into 
water, carbon dioxide, and lactic acid. The dose and release 
pattern of the everolimus is the same one used for the Xience 
V stent (Abbot Vascular). The scaffold is balloon expandable, 
radiolucent, and has two radio-opaque markers in its distal 
ends to facilitate its positioning in the coronary artery.
There are two designs of the BVS that have been tried in 
clinical trials. In Cohort A of the ABSORB (A   Clinical Evalu-
ation of the Bioabsorbable Everolimus Eluting   Coronary Stent 
System in the Treatment of Patients With de Novo Native 
Coronary Artery Lesions) trial, the design was the BVS 1.0. 
This scaffold has a circumferential   out-of-phase zigzag hoops 
design and provided radial support to the vessel for only 
weeks, having an absorption time of approximately 2 years.22 
The new version used in Cohort B (BVS 1.1) has modifica-
tions in the platform design (in-phase zigzag hoops linked by 
bridges) and in polymer processing, in order to improve the 
mechanical strength and to reduce early and late recoil. The 
degradation process is slower in the second   version to provide 
longer mechanical support to the vessel.23
BVS clinical results
The available clinical results of the performance of the BVS 
come from the ABSORB trial (Figure 1). ABSORB Cohort 
A was a single-arm, prospective, open-label, first-in-humans 
Clinical outcomes
30 patients
Cohort A
ABSORB
Cohort B
Group B1 Group B2
101 patients
Up to 2 de novo lesions
Stable angina, unstable angina,
silent ischemia
Safety and performance 
of the BVS 1.1
Clinical outcomes
Invasive imaging
at 6 and 
24 months
56 patients 45 patients
Invasive imaging
at 12 and 
36 months
Single de novo lesion
Stable angina, unstable angina,
silent ischemia
Safety and performance 
of the BVS 1.0
Imaging outcomes at 6 months 
and 2 years
Figure 1 Overview of the ABSORB (A Clinical Evaluation of the Bioabsorbable Everolimus Eluting Coronary Stent System in the Treatment of Patients with de Novo Native 
Coronary Artery Lesions) Cohort A and B trials. 
Abbreviation: BVS, everolimus-eluting polylactide scaffold.
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study with safety and imaging endpoints. Between March 
2006 and July 2006, Cohort A enrolled 30 patients with stable 
angina, unstable angina, or silent ischemia and a single de 
novo lesion in a native coronary artery of 3.0 mm. Patients 
were treated with the BVS 1.0 version, and there were 
two available stent lengths (12 mm and 18 mm). Clinical 
endpoints were cardiac death, myocardial infarction (MI), 
  ischemia-driven target lesion revascularization (TLR), 
ischemia-driven major adverse cardiac event (MACE) (com-
posite of cardiac death, MI, or ischemia-driven TLR), and 
stent thrombosis. We now have clinical results up to 4 years 
for Cohort A (29 of the 30 patients have follow-up). There 
was only one non-Q-wave MI related to the treatment of a 
nontarget stenosis in a patient with a BVS implanted 46 days 
earlier, resulting in an MACE rate of 3.4%.24 There were no 
cases of cardiac death or scaffold thrombosis up to 4 years. 
This MACE rate has remained unchanged from the 6-month 
follow-up.11,22,25
The ABSORB Cohort B trial is a multicenter, single-arm 
trial assessing the safety and performance of the BVS (Rev.1.1, 
Abbott Vascular) in the treatment of patients with stable angina, 
unstable angina, or silent ischemia and a maximum of two de 
novo native coronary artery lesions with a maximum diameter 
of 3.0 mm and a length of #14 mm. The clinical endpoints 
were similar to Cohort A. The trial enrolled 101 patients, 
45 of whom (Group B1) were randomized to angiographic 
and invasive imaging at 6-month and 24-month follow-up, 
and 56 of whom (Group B2) were randomized to invasive 
follow-up at 12 months and 36 months. At 6-month follow-up 
there were no cases of cardiac death or scaffold thrombosis, 
and the ischemia-driven MACE rate was five out of 101 
(4.9%), three non-Q-wave MIs, and two ischemia-driven PCIs. 
Interestingly, there were no differences in MACE between 
vessels ,2.5 mm or .2.5 mm (three of 41 [7.3%] cases 
in small vessels vs two of 60 [3.3%] in large vessel cases; 
P = 0.3933).26 In Group B2 at 12-month follow-up there were 
two non-Q-wave MIs (one periprocedural and one iatrogenic) 
and two ischemia-driven TLRs, resulting in a MACE of 7.1% 
(four of 56).27 The 2-year follow-up of Cohort B1 (45 patients) 
has recently been presented, showing a MACE rate of 6.8% 
(one non-Q-wave MI and two ischemia-driven TLRs), which 
is unchanged from the 6-month and 1-year follow-ups, with 
no cases of scaffold thrombosis or cardiac death.28
BVS imaging results
The BVS is probably the coronary device that has been 
  studied with more detail in the history of coronary 
  interventions through multiple different invasive and 
  noninvasive imaging modalities. In this section we will 
review the imaging results of the Absorb trial.
Invasive BVS assessment
Angiography
In Cohort A, 2-year angiography showed an in-stent late 
loss of 0.48 ± 0.28 mm, similar to the results at 6 months.11 
In Cohort B, the late loss was 0.19 ± 0.18 mm at 6 months for 
Group B1 and 0.27 ± 0.32 mm at 12 months for Group B2. 
This late loss at 12 months is comparable with that observed 
in historical series of metallic everolimus-eluting stents, with 
a very low restenosis rate.27
Intravascular ultrasound and derived techniques
The quantitative intravascular ultrasound (IVUS) evalua-
tion in Cohort A at 6 months revealed a reduction of 12% 
in the scaffold area without vessel shrinkage, suggesting 
an early recoil phenomenon. This, in addition to intimal 
hyperplastic tissue, resulted in a 16.8% reduction in luminal 
area.22 The 2-year follow-up IVUS showed a significant 
increase in minimal and mean luminal area and a decrease 
in plaque area, without changes in the vessel area between 
6 months and 2 years.11 In Cohort A (BVS 1.0), the scaffold 
was not discernible at 2 years and could not be measured. 
In Cohort B (BVS 1.1), the scaffold remained detectable by 
IVUS for up to 2 years. At 6 months, in Group B1 there was 
no   significant change in vessel area and a small decrease 
in mean scaffold area, minimal scaffold area, mean lumen 
area, and minimum lumen area. The decrease in the mean 
scaffold area was 2% versus the 12% observed in Cohort 
A at 6 months,   demonstrating the improved mechanical 
properties of the BVS 1.1 version.29 The neointimal growth 
was very small, reflecting the effect of the antiproliferative 
drug. At 1-year follow-up, Cohort B2 showed no changes 
in the scaffold area and mean lumen area, with a decrease 
of 1.94% in the minimum lumen area.27 The 2-year results 
in Group B1 showed a modest but significant increase in the 
vessel area, scaffold area, lumen area, and plaque area from 
6 months to 2 years.28
IVUS-derived techniques such as IVUS virtual   histology 
(VH) and echogenicity have been used to evaluate the 
a  bsorption of the scaffold.30–33 The decrease in dense   calcium 
in IVUS-VH and the reduction of hyperechogenic tissue in 
echogenicity analysis have been proposed as surrogate markers 
of ultrasonic alteration of the polymeric struts. In Cohort A, 
there was a progressive reduction of   hyperechogenic tissue 
from the implantation until 2-year follow-up, but the dense 
calcium by VH remained unchanged.11 In Cohort B1, 
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at 6 months, there were no significant changes in dense 
calcium.29 However, in Cohort B2, at 12 months, there 
was a significant decrease in calcium by VH and in tissue 
echogenicity.27
Optical coherence tomography
Optical coherence tomography (OCT) has been one of 
the most useful techniques for evaluating the behavior of 
bioresorbable scaffolds. Apart from giving measurements 
of the lumen and scaffold and assessing in a precise way the 
  apposition and coverage of the scaffold, OCT has provided 
unique insights into the changes of the polymeric struts 
over time. The polymeric struts show in OCT a black box 
  appearance without shadow. This is very different from 
metallic struts, which appear as highly reflective structures 
with dorsal shadow. In Cohort A, it was possible to observe 
important changes in the strut morphology by OCT at 
6 months (and a classification of the different morphologies 
observed was proposed), whereas at 2 years a high propor-
tion of the struts were indiscernible by OCT.11 In Cohort B, 
however, the majority of the struts remain visible with a 
typical box appearance at 1-year follow-up, but a decrease in 
their black core size has been demonstrated and interpreted 
as an early sign of resorption.27 In order to understand the 
meaning of the changes in the polymeric struts observed 
with OCT, a recent study compared the OCT findings with 
corresponding histology in a porcine coronary artery model 
immediately after and at 28 days, 2 years, 3 years, and 
4 years after BVS implantation. The study demonstrated that 
the majority of struts still visible by OCT at 2 years were 
largely resorbed, and the image in OCT corresponded to 
the filling of the previous location of the strut with connec-
tive tissue. OCT was therefore reflecting the integration of 
the struts in the surrounding tissue rather than the absorption 
process.34
Regarding the evaluation of malposition and coverage in 
Cohort A, at 2 years, OCT demonstrated that all the struts 
were covered, and the cases of malposition detected at 
6 months were resolved.11 In Cohort B1, similar results have 
been shown at 2 years, with an almost complete coverage 
of all the struts and a resolution of the majority of cases of 
malposition initially observed.28 Regarding the quantitative 
OCT evaluation in Cohort A, the results were similar to IVUS, 
demonstrating an initial decrease in lumen area at 6 months 
with a subsequent increase at 2 years.11 At 1-year follow-up in 
Cohort B2, mean and minimal scaffold area by OCT did not 
change (again reflecting the improved mechanical strength of 
the BVS 1.1). The mean and   minimal lumen area decreased 
by 18.1% and 23.4% due to mild neointimal growth.27 
At 2-year follow-up in Group B1, OCT demonstrated an 
increase in scaffold area and a small decrease in the mean 
and minimal lumen area, related to a slight increase in the 
neointimal area, which remained very low.28 These results 
reflect the good mechanical performance of the BVS 1.1 and 
the well-controlled neointimal pr  oliferation obtained with 
this device.
Noninvasive BVS assessment
Another potential advantage of bioabsorbable stents would 
be the possibility of being followed up with noninvasive 
imaging techniques such as MSCT scan. In Cohort A of the 
ABSORB trial, patients were followed up with MSCT at 
18 months. MSCT was evaluated in 24 out of the 30 patients, 
demonstrating the feasibility of the technique to demonstrate 
stent patency and to measure mean lumen area, minimum 
lumen area, and   percent area stenosis without the artifacts 
associated with   metallic stents.11 MSCT has also been used 
for scaffold follow-up at 5 years in Cohort A and at 18 months 
in Cohort B.
Vasomotion restoration
It has been demonstrated that permanent metallic   stenting 
  suppresses vasomotion in the stented segment.35 In the 
ABSORB trial, the hypothesis of vasomotion recovery after 
scaffold absorption was tested. Two drugs were used in the 
study to evaluate vasomotion: methylergonovine (which 
induces nonendothelium-dependent vasoconstriction) and 
acetylcholine (Ach) (which induces endothelium-dependent 
direction of flow-mediated vasodilatation). The vasodilator 
response to Ach could therefore suggest the presence of 
  functionally active endothelium. In Cohort A, at 2 years, five 
of nine patients tested with Ach showed vasodilatation at 
the site of the scaffold implantation. In Cohort B2, at 1-year 
follow-up, ten of 19 analyzable patients who received Ach 
showed   vasoconstriction of the scaffolded segments, eight 
showed vasodilation, and one did not have any vasomotion. 
These results suggest that in the majority of patients there 
was not a complete recovery of the normal endothelium in 
the scaffolded segments at the time when follow-up was 
performed.27
Other bioabsorbable coronary 
stents
Igaki-Tamai stent
This was the first fully bioabsorbable stent implanted in 
humans more than 10 years ago. It is composed of PLLA, 
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has a degradation time of around 2 years, and does not have 
drug elution. The stent expanded by itself using heated con-
trast to inflate the delivery balloon. PLLA is radiolucent, and 
two markers are required for placement. In the first-in-human 
study, a total of 25 stents were successfully implanted in 
19 lesions in 15 patients. At 30 days, no stent thrombosis and 
no major cardiac event occurred, and at 6 months there was 
only one repeat revascularization.36 A second study including 
50 patients (63 lesions, 84 stents) also showed good clinical 
results, with a survival rate of 97.7% and an MACE-free 
rate of 82%.23 Even with these promising clinical results, the 
clinical use of the stent for coronary arteries did not extend, 
mainly because of the complex implantation procedure with 
the thermal balloon.
Magnesium alloy stents
Magnesium is a biocompatible metal and is common in 
the human body. The first generation of magnesium alloy 
stent (AMS-1; Biotronik, Berlin, Germany) was balloon 
  expandable, did not have drug elution, and was radiolucent, 
showing good mechanical properties with radial strength 
at implantation similar to those of stainless steel stents. 
This stent was tested in the PROGRESS AMS (Clinical 
  Performance and Angiographic Results of Coronary   Stenting 
with A  bsorbable Metal Stents) trial, where 71 stents were 
implanted in 63 patients with simple de novo   stenosis. 
The authors d  emonstrated that the stent was resorbed 
(at 4-month follow-up only small remnants of the original 
struts were visible in IVUS). Further, they showed a recovery 
of the vasodilator function after nitroglycerin in the treated 
segment.37 There were no deaths, MI, or stent thrombosis 
at 12 months, but the restenosis rate was high, with target 
vessel revascularization at 1 year of 45%.38 IVUS analysis 
  demonstrated that early recoil attributable to the loss of radial 
force from a too fast degradation was probably the cause of 
the high rates of restenosis in these stents.39 New develop-
ments in this field are oriented to prolong the degradation 
time to avoid the early recoil (AMS-2) and to incorporate 
drug elution in order to avoid excessive neointimal growth 
(AMS-3).
Tyrosine polycarbonate polymer:  
REVA stent
The REVA stent (Reva Medical Inc, San Diego, CA) is made 
of an absorbable tyrosine-derived polycarbonate polymer 
that metabolizes to amino acids, ethanol, and   carbon dioxide. 
The polymer is impregnated with iodine to increase its 
r  adio-opacity. It is balloon expandable and the degradation 
time is around 2 years but depends on the molecular weight 
of the polymer. Preclinical studies demonstrated good 
m  echanical properties with a good radial force. The stent that 
was nondrug eluting was tested first in humans in RESORB 
(REVA   Endovascular Study of a Bioresorbable Coronary 
Stent), a prospective, nonrandomized, single-arm, safety study 
that enrolled 27 patients. The study showed a high TLR rate 
(66.7%) between 4 months and 6 months due to focal mechani-
cal failures.40 This has led to a new design, the ReZolve stent, 
which has improved robustness of the polymer and is able to 
elute sirolimus.
Sirolimus-eluting-poly(anhydride ester)
salicylic acid: the IDEAL stent
The IDEAL stent (Bioabsorbable Therapeutics Inc, 
Menlo Park, CA) is a fully bioabsorbable sirolimus-eluting 
stent that also releases salicylic acid. This stent has both 
  antiproliferative and anti-inflammatory properties. It is bal-
loon expandable and the degradation time is 9–12 months. 
It degrades into salicylate, carbon dioxide, and water. 
The first-in-humans study with the stent (WHISPER [IDEAL 
Bioabsorbable Coronary Stent Platform Eluting Sirolimus] 
study) enrolled eleven patients. There was no evidence 
of acute or chronic recoil, but the neointimal growth was 
  excessive. A new design is under development, with a new 
drug dosing and release pattern and modifications in the stent 
design.41,42
Conclusion
Absorbable stents appear as one of the most promising fields 
in interventional cardiology, with several potential advan-
tages over permanent metallic stents. Professor Serruys, 
one of the pioneers in PCIs, has named them “the fourth 
revolution” after balloon angioplasty, bare-metal stents, and 
drug-eluting stents.23 The ABSORB Cohort A and B trials 
have shown the safety and efficacy of the BVS in simple 
lesions in stable patients. Larger studies are required to 
evaluate the performance of the device in other clinical and 
angiographic scenarios. Further, the results of the absorbable 
scaffold need to be compared in randomized trials against the 
second-generation drug-eluting stents. Research in the field 
is active, and new trials are already planned to determine the 
place in therapy of these devices.
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